Recombinant human epoetin beta in the treatment of renal anemia

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 433-439

  Locatelli, Francesco ^a   Pozzoni, Pietro ^a   Del Vecchio, Lucia ^b  

^a A MANZONI HOSPITAL   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; Epoetin beta

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD VESSEL GRAFT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; PURE RED CELL ANEMIA; QUALITY OF LIFE; REVIEW;

EID: 34547700944     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Abraham PA, Macres MG. 1991. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol, 2:927-36.
2. Albetazzi A, Di Liberato L, Daniele F et al. 1998. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs, 21:12-18.
3. Anand IS, Chandrashekhar Y, Ferrari R, et al. 1993. Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J, 70:357-62.
4. Astor BC, Muntner P, Levin A, et al. 2002. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med, 162:1401-8.
5. Bennett WM. 1991. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol, 1:990-8.
6. Bennett CL, Luminari S, Nissenson AR, et al. 2004. Pure red-cell aplasia and epoetin therapy. N Engl J Med, 351:1403-8.
7. Besarab A, Bolton WK, Browne JK, et al. 1998. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med, 339:584-90.
8. Besarab A, Flaharty KK, Erslev AJ, et al. 1992. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol, 2:1405-16.
9. Besarab A, Reyes CM, Homberger J. 2002. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis, 40:439-46.
10. Bommer J, Kugel M, Schoeppe W, et al. 1998. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol, 66:85-93.
11. Casadevall N, Nataf J, Viron B, et al. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med, 346:469-75.
12. Collins AJ, Kasiske B, Herzog C, et al. 2005. The United States Renal Data System 2004 annual data report. Am J Kidney Dis, 45(Suppl 1).
13. Collins AJ, Li S, St Peter W, et al. 2001. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol, 12:2465-73.
14. Eschbach JW, Egrie JC, Downing MR, et al. 1987. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med, 316:73-8.
15. Foley RN, Murray AM, Li S, et al. 2005. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol, 16:489-95.
16. Foley RN, Parfrey PS, Harnett JD, et al. 1996. The impact of anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis, 28:53-61.
17. Foley RN, Parfrey PS, Morgan J, et al. 2000. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int, 58:1325-35.
18. Foley RN, Parfrey PS, Sarnak MJ. 1998. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis, 32(Suppl 3):S112-19.
19. Frank H, Heusser K, Hoffken B, et al. 2004. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int, 66:832-40.
20. Frifelt JJ, Tvedegaard E, Bruun K, et al. 1996. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int, 16:594-8.
21. Furuland H, Linde T, Ahlmen J, et al. 2003. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant, 18:353-61.
22. Grzeszczak W, Sulowicz W, Rutkowski B, et al. 2005. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta is effective in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant, 20:936-4.
23. Halstenson CE, Macres M, Kats Sa, et al. 1991. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther, 50:702-12.
24. Harnett JD, Kent GM, Foley RN, et al. 1995. Cardiac function and hematocrit level. Am J Kidney Dis, 25(Suppl 1):S3-7.
25. Hayashi T, Suzuki A, Shoji T, et al. 2000. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis, 35:250-6.
26. Hynes DM, Stroupe KT, Greer JW, et al. 2002. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med, 112:169-75.
27. Jungers P, Choukroun G, Oualim Z, et al. 2001. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant, 16:307-12.
28. Kaizu K, Uriu K, Eto S. 1993. Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure. Japan J Nephrol, 35:989-97.
29. Kaufman JS, Reda DJ, Fye CL, et al. 1998. Subcutaneous compared with intravenous epoctin inpatients receiving hemodialysis. N Engl J Med, 339:578-83.
30. Kaupke CJ, Vaziri ND, Sampson JR, et al. 1990. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients. Int J Artif Organs, 13:218-22.
31. KDOQI; National Kidney Foundation. 2006. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis, 47(Suppl 3):S11-145.
32. Keith DS, Nichols GA, Gullion CM, et al. 2004. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med; 164:659-63.
33. Kleophas W, Kult J, Kreusser W, et al on behalf of the Collaborative Study Group. 2003. Tolerability and efficacy of multidose epoetin beta (RecoPen®) for subcutaneous administration in patients with anemia due to renal failure. Kidney Blood Press Res, 26:192-8.
34. Koch KM, Koene RA, Messinger D, et al. 1995. The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol, 44:201-8.
35. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. 2006. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int, 69:560-4.
36. Kuriyama S, Tomonary H, Yoshida H, et al. 1997. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron, 77:176-85.
37. Levin A. 2001. Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant, 16(Suppl 2):7-11.
38. Levin A. 2002. The role of anemia in the genesis of cardiac abnormalities in patients with chronic kidney disease. Nephrol Dial Transplant, 17:207-10.
39. Levin A, Djurdjev O, Duncan J, et al. 2006. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant, 21:370-7.
40. Levin A, Djurdjev O, Thompson C, et al. 2005. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis, 46:799-811.
41. Levin A, Thompson CR, Ethier J, et al. 1999. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis, 34:125-34.
42. Lin FK, Suggs S, Lin CH, et al. 1985. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A, 82:7580-4.
43. Locatelli F, Aljama P, Barany P, et al; European Best Practice Guidelines Working Group. 2004. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant, 19 (Suppl 2):ii1-47.
44. Locatelli F, Aljama P, Barany P, et al. 2004b. Erythropoietic proteins and antibody-mediated pure red cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant, 19:288-93.
45. Locatelli F, Baldamus CA, Villa G, et al; on behalf of the Study Group. 2002. Once weekly compared with three-times weekly subcutaneous epoetin β: results from a randomized, multicenter, therapeutic equivalence study. Am J Kidney Dis, 40:119-25.
46. Locatelli F, Marcelli D, Conte F, et al. 2000. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant, 15(Suppl 5):69-80.
47. Locatelli F, Pisoni RL, Combe C, et al. 2004. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant, 19:121-32.
48. Lui SF, Law CB, Ting SM, et al. 1991. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol, 36:246-51.
49. Ma J, Ebben J, Xia H, Collins A. 1999. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol, 10:610-19.
50. Madore F, Lowrie EG, Brugnara C, et al. 1997. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol, 8:1921-9.
51. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. 2000. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol, 11:335-42.
52. Navarro JF, Teruel JL, Marcen R, et al. 1995. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol, 29:11-14.
53. Nomato Y, Kawaguchi Y, Kubota M, et al. 1994. A multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int, 14:56-60.
54. Parfrey PS, Foley RN, Harnett JD, et al. 1996. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant, 11:1277-85.
55. Parfrey PS, Foley RN, Wittreich BH, et al. 2005. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol, 16:2180-9.
56. Portoles J, Torralbo A, Martin P, et al. 1997. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis, 29:541-8.
57. Regidor DL, Kopple JD, Kovesdy CP, et al. 2006. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol, 17:1181-91.
58. Robinson BM, Joffe MM, Berns JS, et al. 2005. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated overtime. Kidney Int, 68:2323-30.
59. Roger SD, McMahon LP, Clarkson A, et al. 2004. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol, 15:148-56.
60. Rossert J, Levin A, Roger SD, et al. 2006. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis, 47:738-50.
61. Rossert J, McClellan WM, Roger SD et al. 2002. Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant, 17:359-62.
62. Saleh A, Krane NK, Caballero M, et al. 1991. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. Adv Perit Dial, 7:288-91.
63. Silverberg D. 2003. Outcomes of anemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant, 18(SuppI 2):ii7-ii12.
64. Sinnassamy P, Andre JL, Treize G, et al. 1993. Effect of treatment with human recombinant erythropoietin on the anemia of children with end-stage renal failure. French multicentre study. Arch Fr Pediatr, 50:201-8.
65. Storring PL, Tiplady RJ, Gaines Das RE, et al. 1998. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol, 100:79-89.
66. Thomas S, Rampersad M. 2004. Anaemia in diabetes. Acta Diabetologica, 41(Suppl 1):S13-17.
67. Volkova N, Arab L. 2006. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis, 47:24-36.
68. Weiss LG, Clyne N, Divino Fihlho, et al; on behalf of the Swedish Study Group. 2000. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant, 15:2014-19.
69. Winearls CG, Oliver DO, Pippard MJ, et al. 1986. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet, 2:1175-8.